Monkey Jackfruit

Artocarpus lakoocha contains oxyresveratrol, artocarpesin, and prenylated flavonoids concentrated in the heartwood and bark that modulate Nrf2/HO-1/NQO1 antioxidant pathways and inhibit eicosanoid-mediated inflammatory signaling. Preclinical evidence demonstrates significant antioxidant capacity in bark extracts (CUPRAC: 91.32±3.77 mg AEAC/g) and anti-melanogenic and anti-inflammatory activity in vitro, though no human clinical trials have yet confirmed therapeutic doses or effect sizes in patients.

Origin & History

Artocarpus lakoocha Roxb. is native to South and Southeast Asia, distributed across India, Thailand, Myanmar, Malaysia, and parts of Indonesia, where it grows in tropical lowland and monsoon forests up to approximately 1,000 meters elevation. The tree thrives in well-drained, fertile soils with high humidity and is commonly found along riverbanks and in mixed deciduous forests. In Thailand, India, and Myanmar it has been cultivated semi-domestically near villages for both food and medicinal purposes for centuries.

Historical & Cultural Context

Artocarpus lakoocha, commonly called monkey jackfruit or Lakoocha, has been documented in Thai, Ayurvedic, and Burmese traditional medicine systems for centuries, where the bark and heartwood were employed as astringents and anti-inflammatory agents for skin wounds, dermatitis, and febrile conditions. In Thai traditional medicine, the heartwood decoction was specifically applied topically for wound healing and as an antifungal preparation, with its reddish heartwood recognized as the medicinally potent part of the tree. The fruit has longstanding culinary use across India, Thailand, and Myanmar, eaten fresh or pickled, and its seeds are occasionally used as food after cooking. Regional vernacular names including 'Lakoocha' (Bengali/Hindi), 'Phak khanun' variations (Thai), and 'Monkey Jack' (English colonial nomenclature) reflect its wide ethnobotanical recognition across diverse cultural systems.

Health Benefits

- **Anti-inflammatory Activity**: The stilbenoid oxyresveratrol and prenylated flavonoids in the bark and heartwood suppress arachidonic acid cascade signaling, reducing pro-inflammatory eicosanoid production relevant to wound healing applications documented in Thai ethnomedicine.
- **Antioxidant Defense Upregulation**: Bark and leaf extracts activate the Nrf2 transcription factor at concentrations as low as 5 µg/mL, increasing expression of cytoprotective enzymes NQO1 and HO-1 that neutralize reactive oxygen species.
- **Wound Healing Support**: Traditional Thai medicine employs bark and heartwood preparations topically for wound management, a use supported by demonstrated antimicrobial activity against skin-relevant pathogens in laboratory susceptibility testing.
- **Anti-melanogenic Properties**: Oxyresveratrol from the heartwood inhibits tyrosinase enzyme activity, the rate-limiting step in melanin biosynthesis, making it relevant to hyperpigmentation management in topical cosmetic formulations.
- **Antimicrobial Activity**: Ethanolic and methanolic extracts from multiple plant parts have demonstrated inhibitory activity against bacterial and fungal pathogens in disc-diffusion and MIC assays, with the bark showing particularly broad-spectrum activity.
- **Hepatoprotective Potential**: Triterpenoids including lupeol and lupeol acetate identified in the bark are associated with mitochondrial protection and redox modulation, paralleling hepatoprotective mechanisms documented for these compound classes in other botanical sources.
- **Nutritional Antioxidant Contribution**: The fruit provides vitamin C (~13.4 mg per 100 g) alongside phenolic compounds, offering modest dietary antioxidant intake when consumed fresh as part of traditional Southeast Asian diets.

How It Works

Oxyresveratrol (ORV), the predominant stilbenoid in the heartwood, exerts anti-inflammatory effects by inhibiting cyclooxygenase and lipoxygenase enzymes within the arachidonic acid pathway, reducing prostaglandin and leukotriene synthesis. Concurrently, A. lakoocha extracts activate the Nrf2-Keap1 signaling axis: at 5 µg/mL, Nrf2 protein expression increases, driving transcription of phase-II antioxidant enzymes including NQO1 (upregulated across 1–20 µg/mL) and HO-1 (upregulated from 10 µg/mL), which collectively detoxify electrophiles and reduce oxidative stress burden. Oxyresveratrol additionally inhibits tyrosinase through competitive or mixed-mode enzyme inhibition, blocking the hydroxylation of L-tyrosine to L-DOPA and subsequent melanin polymerization. Lupeol and lupeol acetate triterpenoids contribute mitochondrial membrane stabilization and redox modulation, potentially synergizing with the stilbenoid fraction to produce the observed cytoprotective phenotype in cell-based assays.

Scientific Research

The available evidence base for Artocarpus lakoocha consists entirely of in vitro phytochemical screening, antioxidant capacity assays (DPPH and CUPRAC methods), antimicrobial susceptibility testing, and cell-based mechanistic studies; no published human clinical trials with defined sample sizes or effect sizes have been identified as of the current literature review. Antioxidant studies quantify bark extract capacity at 7.19±0.10 mg AEAC/g by DPPH and 91.32±3.77 mg AEAC/g by CUPRAC, providing reproducible in vitro benchmarks but not translatable therapeutic doses. Mechanistic cell studies documenting Nrf2, HO-1, and NQO1 expression changes are rigorous at the in vitro level but have not been replicated in animal pharmacology models with full dose-response characterization for most endpoints. The overall evidence quality is preclinical and exploratory, placing this ingredient firmly in a hypothesis-generating phase; well-designed animal studies followed by Phase I human safety trials are needed before any evidence-based clinical recommendation can be issued.

Clinical Summary

No human clinical trials investigating Artocarpus lakoocha as a therapeutic or nutraceutical intervention have been published in the peer-reviewed literature available to date. All mechanistic and efficacy data derive from in vitro cell culture experiments and phytochemical characterization studies, which, while methodologically sound, cannot establish human pharmacokinetics, effective doses, or clinical outcomes. The absence of animal pharmacology studies with full ADME profiling represents an additional evidence gap that precedes any ethical pathway to human trials. Confidence in clinical benefit claims must therefore be rated as low; traditional ethnomedicinal use in Thai and South Asian contexts provides contextual plausibility but does not substitute for controlled clinical evidence.

Nutritional Profile

The fruit of A. lakoocha contains approximately 75.5% moisture, 0.24% protein, 0.63% fat, and 2.47% crude dietary fiber per 100 g fresh weight, making it a low-calorie fruit with modest macronutrient density. Vitamin C content is approximately 13.4 mg per 100 g, providing a minor but meaningful dietary antioxidant contribution. The bark is the richest source of total phenols (10.14±0.72 g GAE per 100 g), while leaves carry the highest flavonoid content (17.13±1.77 g QE per 100 g), concentrations that far exceed the fruit and reflect the medicinal parts' phytochemical density. Key identified phytochemicals include oxyresveratrol, artocarpesin, catechin, moracin, cyclocommunin, lakoochanone, lakoochanosides, lupeol, and lupeol acetate; bioavailability of these compounds from oral consumption has not been characterized in human pharmacokinetic studies, and the matrix effects of traditional preparation methods on compound stability and absorption remain unknown.

Preparation & Dosage

- **Traditional Topical Preparation (Bark Poultice)**: Powdered or macerated bark of A. lakoocha applied directly to wounds or inflamed skin as a paste; no standardized concentration or duration established.
- **Ethanolic Bark Extract (Research Grade)**: Laboratory studies employ 70–95% ethanol extraction; no standardized human supplemental dose has been established from clinical data.
- **Methanolic Leaf Extract**: Used in antimicrobial and antioxidant assays at test concentrations of 1–20 µg/mL in cell studies; direct translation to oral or topical human doses is not yet validated.
- **Fresh Fruit (Dietary)**: Consumed fresh in Southeast Asian diets; nutritional contribution includes ~13.4 mg vitamin C per 100 g and dietary fiber (~2.47%), but no therapeutic dosing applies.
- **Cosmetic/Topical Oxyresveratrol Standardized Extract**: Emerging use in skin-lightening formulations; oxyresveratrol concentrations used in cosmetic research typically range from 0.1–1% w/v in topical vehicles, though no regulatory standardization exists.
- **Dosage Note**: No evidence-based supplemental dose range, bioavailability parameter, or standardization percentage (e.g., % oxyresveratrol) has been established for oral human use; all dose extrapolation from in vitro data remains speculative.

Synergy & Pairings

Oxyresveratrol from A. lakoocha may exhibit additive or synergistic antioxidant activity when combined with other Nrf2-activating polyphenols such as quercetin or curcumin, as convergent activation of the Nrf2-Keap1 pathway through structurally distinct ligands can amplify phase-II enzyme induction beyond what either compound achieves alone. In topical anti-melanogenic formulations, pairing oxyresveratrol with kojic acid or alpha-arbutin—compounds that inhibit tyrosinase through complementary non-competitive mechanisms—has been explored in cosmetic research to achieve broader pigmentation control at lower individual concentrations. The catechin content of A. lakoocha bark may synergize with vitamin C (ascorbic acid) through redox recycling, where ascorbate regenerates oxidized catechin radicals, extending the effective antioxidant half-life of both compounds in formulations.

Safety & Interactions

Comprehensive human safety data, including adverse effect profiles, maximum tolerated doses, and formal drug interaction studies, are absent from the published literature for Artocarpus lakoocha in any form. No regulatory body has established an acceptable daily intake or tolerable upper limit for bark, leaf, or heartwood extracts; consumption of the fresh fruit at normal dietary quantities is generally regarded as safe based on longstanding traditional use across multiple Asian populations without documented reports of acute toxicity. Given that oxyresveratrol shares structural similarity with resveratrol, theoretical interactions with CYP450 enzymes (particularly CYP1A2 and CYP3A4) and anticoagulant medications cannot be excluded, though no empirical interaction data exist for this specific compound from A. lakoocha sources. Pregnancy and lactation safety is entirely unstudied; in the absence of safety data, use of concentrated extracts (bark, heartwood, or standardized oxyresveratrol) beyond normal dietary fruit consumption is not advisable during pregnancy or breastfeeding.